兰克尔
癌症研究
骨溶解
MMP9公司
间质细胞
静脉注射
骨转移
乳腺肿瘤
转移
同基因
肿瘤微环境
癌细胞
基质金属蛋白酶
乳腺癌
化学
下调和上调
癌症
病理
医学
受体
内科学
激活剂(遗传学)
移植
外科
基因
肿瘤细胞
生物化学
作者
Kalyan C. Nannuru,Mitsuru Futakuchi,Michelle L. Varney,Thomas M. Vincent,Eric G. Marcusson,Rakesh K. Singh
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2010-04-28
卷期号:70 (9): 3494-3504
被引量:144
标识
DOI:10.1158/0008-5472.can-09-3251
摘要
The tropism of breast cancer cells for bone and their tendency to induce an osteolytic phenotype are a result of interactions between breast cancer cells and stromal cells and are of paramount importance for bone metastasis. However, the underlying molecular mechanisms remain poorly understood. We hypothesize that tumor-stromal interaction alters gene expression in malignant tumor cells and stromal cells creating a unique expression signature that promotes osteolytic breast cancer bone metastasis and that inhibition of such interactions can be developed as targeted therapeutics. Microarray analysis was performed to investigate gene expression profiling at the tumor-bone (TB) interface versus the tumor alone area from syngenic mice injected with three different syngenic mammary tumor cell lines that differ in their metastatic potential. We identified matrix metalloproteinase 13 (MMP13), receptor activator of NF-kappaB ligand (RANKL), and integrins binding sialoprotein to be genes upregulated at the TB interface and validated. To determine the functional role of MMP13 in tumor-induced osteolysis, mice with Cl66 mammary tumors were treated with MMP13 antisense oligonucleotides (MMP13-ASO) or control scrambled oligonucleotides (control-ASO). Knockdown of MMP13 expression at the TB interface leads to significant reduction in bone destruction and in the number of activated osteoclasts at the TB interface. Further analysis to evaluate the mechanism of MMP13-dependent osteolytic bone metastasis revealed that MMP13-ASO treatment decreased active MMP9, RANKL levels, and transforming growth factor-beta signaling at the TB interface. Together, our data indicate that upregulation of MMP13 at the TB interface is important in tumor-induced osteolysis and suggest that MMP13 is a potential therapeutic target for breast cancer bone metastasis.
科研通智能强力驱动
Strongly Powered by AbleSci AI